Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.
about
Recent developments in clinical trial designs for HIV vaccine researchPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesEpitope specific T-cell responses against influenza A in a healthy population.Response definition criteria for ELISPOT assays revisitedPeptide impurities in commercial synthetic peptides and their implications for vaccine trial assessmentOptimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trialsEquivalence of ELISpot assays demonstrated between major HIV network laboratoriesStatistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry.Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trialPersistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tractHost genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.Study of the BCG Vaccine-Induced Cellular Immune Response in Schoolchildren in Antananarivo, MadagascarPooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vectorDefining ELISpot cut-offs from unreplicated test and control wells.Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studiesQuantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners.Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.Statistical estimation & inference of cell counts from ELISPOT limiting dilution assaysGeneration of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer.Normal Distribution of CD8+ T-Cell-Derived ELISPOT Counts within Replicates Justifies the Reliance on Parametric Statistics for Identifying Positive Responses.Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis.Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients.Long-term toxicity, pharmacokinetics and immune effects of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates.
P2860
Q28083514-847E7404-BEA1-403A-BB29-1F9D683D4EB3Q28749120-90BB65BB-F0F7-457A-8FAC-C7BEE09769CBQ30202358-BE8E4116-4812-4B81-AE9E-0908AD45EEA2Q30495664-8F4045F6-8CAE-46DA-9FF5-2AB00CF7A977Q33310152-0C953295-22AA-4614-94DE-B2554812E198Q33611244-D97CABC3-C3D6-4E42-9393-28626E998857Q33778327-01B228E4-1861-43E5-BC59-335A6E3D7D5EQ33923216-DD94E6BE-C26C-483F-8BD7-3FA36701E3D6Q34023588-E3EA152D-3704-4D5B-B269-E09276C25A9EQ34229329-95A44D5B-CBE5-49F4-AAE3-0E2DC2575727Q34263835-942406A7-1F40-476E-819B-673510132262Q34592982-F64CF909-1C24-492B-BAA5-DAF3F48822C9Q34663554-66E5D599-15FA-4254-BFA7-C122A8CCAFDCQ34681733-B19505C9-A756-49D6-AEBF-F11516BA1D11Q34764031-B074768C-BF15-449D-9330-3D8B54DAA8CAQ35202180-085A431F-4F40-434D-B10C-AA7F3FC54AA8Q35567414-F410AA5E-B910-4446-B7C1-AAE75E1D32B2Q35611969-B37C8620-E048-4A94-8D3D-42AEB02EB5D8Q35716201-118BD49C-F5D5-4DC4-B6B6-F2B935352C07Q35919760-605EBF21-4535-41CA-86E6-F7AA05ADE013Q36362287-04E47EE7-2771-466F-A7ED-553779448799Q36720991-0D8261C6-20D6-4629-A33E-E0C6A6FDBAF1Q36852775-4BAD8F91-06B1-4CC8-A1B4-5954643A01ADQ36880258-654980BF-CD55-4BDF-A21E-1F4E4C61E1BAQ37123237-5B84C69C-80FD-4E85-BA76-6DF831142329Q37216571-1652CA50-B4E2-4F4A-87DF-DEBBD7EDDD07Q37243043-815414AE-D853-4FB1-9EF7-78AC68DCC810Q38923514-79F23F34-E54B-41EC-9D8D-C93B2E6F0122Q41298352-67EF36EA-419E-4195-96FE-524E17C765B2Q41642827-54F4A476-5DA5-4C22-85E8-5B17D9D0AA43Q47596485-48355C85-3D57-4ED5-9D47-A9C2ED5E32A4Q52822549-1EDA32E7-5635-447B-AAB8-A6C0315A6902Q54968953-202A659F-04DC-49A4-AB31-175901E2ACD9
P2860
Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Statistical positivity criteri ...... data in HIV-1 vaccine trials.
@ast
Statistical positivity criteri ...... data in HIV-1 vaccine trials.
@en
type
label
Statistical positivity criteri ...... data in HIV-1 vaccine trials.
@ast
Statistical positivity criteri ...... data in HIV-1 vaccine trials.
@en
prefLabel
Statistical positivity criteri ...... data in HIV-1 vaccine trials.
@ast
Statistical positivity criteri ...... data in HIV-1 vaccine trials.
@en
P2093
P1476
Statistical positivity criteri ...... data in HIV-1 vaccine trials.
@en
P2093
John Hural
Steven G Self
Zoe Moodie
P304
P356
10.1016/J.JIM.2006.07.015
P50
P577
2006-08-15T00:00:00Z